Inhibikase Therapeutics, Inc. Business Finance Contracts & Agreements
39 Contracts & Agreements
- Equity Distribution Agreements (1 contract)
- Loan Agreements (4)
- Note Agreements (6)
- Purchase Agreements (2)
- Registration Rights Agreements (1)
- Stock Agreements (2)
- Subscription Agreements (4)
- Underwriting Agreements (3)
- Warrant Agreements (16)
- Registration Rights Agreement, dated as of January 25, 2023 (PIPE) (Filed With SEC on January 26, 2023)
- Securities Purchase Agreement, dated as of January 25, 2023 (PIPE) (Filed With SEC on January 26, 2023)
- Securities Purchase Agreement, dated as of January 25, 2023 (Registered Direct) (Filed With SEC on January 26, 2023)
- Form of Placement Agent Warrant (Filed With SEC on January 26, 2023)
- Form of PIPE Common Warrant (Filed With SEC on January 26, 2023)
- Form of PIPE Pre-Funded Warrant (Filed With SEC on January 26, 2023)
- Form of Private Common Warrant (Filed With SEC on January 26, 2023)
- Form of Pre-Funded Warrant (Filed With SEC on January 26, 2023)
- Equity Distribution Agreement, dated May 16, 2022, by and between Inhibikase Therapeutics, Inc. and Piper Sandler & Co (Filed With SEC on May 17, 2022)
- Form of Stock Option Grant Notice and Award Agreement (Filed With SEC on March 8, 2022)
- Form of Representatives Warrant Agreement (Filed With SEC on June 16, 2021)
- Underwriting Agreement dated June 15, 2021 by and between Inhibikase Therapeutics, Inc. and ThinkEquity, a division of Fordham Financial Management, Inc., as representative of the... (Filed With SEC on June 16, 2021)
- Form of Representatives Warrant (Filed With SEC on June 11, 2021)
- Form of Underwriting Agreement (Filed With SEC on June 11, 2021)
- Amendment to Promissory Note by and between Inhibikase Therapeutics, Inc. and Flagship Consulting, Inc., dated October (Filed With SEC on November 3, 2020)
- Convertible Revolving Demand Promissory Note, issued by Inhibikase Therapeutics, Inc. to Flagship Consulting Inc., dated April 3, 2018 (Filed With SEC on September 15, 2020)
- Letter Agreement to Restated Agreement to Repay Individual Loan, by and between Inhibikase Therapeutics, Inc. and Milton H. Werner, dated September 11, 2020 (Filed With SEC on September 15, 2020)
- Agreement to Repay Individual Loan, by and between Inhibikase Therapeutics, Inc. and Milton H. Werner, dated February 5, 2020 (Filed With SEC on September 15, 2020)
- Amended and Restated Second Convertible Revolving Demand Promissory 2020 Note, issued by Inhibikase Therapeutics, Inc. to Flagship Consulting, Inc., dated August 31, 2020 (Filed With SEC on September 15, 2020)
- Warrant, issued by Inhibikase Therapeutics, Inc. to Flagship Consulting, Inc., dated August 25, 2020 (Filed With SEC on September 15, 2020)
- Warrant, issued by Inhibikase Therapeutics, Inc. to Flagship Consulting, Inc., dated August 25, 2020 (Filed With SEC on September 15, 2020)
- Restated Agreement to Repay Individual Loan, by and between Inhibikase Therapeutics Inc. and Milton H. Werner, Ph.D., dated June 13, 2020 (Filed With SEC on September 15, 2020)
- Warrant, issued by Inhibikase Therapeutics, Inc. to Francis E. McDaniel, dated January 1, 2019 (Filed With SEC on September 15, 2020)
- Side Letter to Subscription Agreement of Joseph Ventures Allium, LLC, dated June 15, 2018 (Filed With SEC on July 23, 2020)
- Side Letter to Subscription Agreement of Joseph Ventures Allium, LLC, dated August 31, 2018 (Filed With SEC on July 23, 2020)
- Side Letter to Subscription Agreement of Joseph Ventures Allium, LLC, dated July 19, 2018 (Filed With SEC on July 23, 2020)
- Form of Inhibikase Therapeutics, Inc. Subscription Agreement (Filed With SEC on July 23, 2020)
- Fifth Restatement and Amendment to Promissory Note, issued by Inhibikase Therapeutics, Inc. to McDaniel Law Firm, PC, dated June 30, 2020 (Filed With SEC on July 23, 2020)
- Restated Agreement to Repay Individual Loan, by and between Inhibikase Therapeutics Inc. and Milton H. Werner, Ph.D., dated June 13, 2020 (Filed With SEC on July 23, 2020)
- Second Convertible Revolving Demand Promissory 2019 Note, issued by Inhibikase Therapeutics, Inc. to Joseph Frattaroli, dated December 31, 2019 (Filed With SEC on July 23, 2020)
- Convertible Revolving Demand Promissory Note, issued by Inhibikase Therapeutics, Inc. to Flagship Consulting, Inc., dated April 3, 2018 (Filed With SEC on July 23, 2020)
- Form of Late IPO Warrant (Filed With SEC on July 23, 2020)
- Form of Representatives Warrant (Filed With SEC on July 23, 2020)
- Warrant, issued by Inhibikase Therapeutics, Inc. to Francis E. McDaniel, dated March 31, 2020 (Filed With SEC on July 23, 2020)
- Warrant, issued by Inhibikase Therapeutics, Inc. to Francis E. McDaniel, dated January 1, 2020 (Filed With SEC on July 23, 2020)
- Warrant dated October 5, 2018, issued by Inhibikase Therapeutics, Inc. to Kubera North America, Inc (Filed With SEC on July 23, 2020)
- Form of Warrant to purchase common stock of the Registrant, issued to each of the investors named in Schedule A thereto (Filed With SEC on July 23, 2020)
- Specimen common stock Certificate of the Registrant (Filed With SEC on July 23, 2020)
- Form of Underwriting Agreement, including the Form of Lock-Up Agreement (Filed With SEC on July 23, 2020)